Identify and validate the most
biologically relevant small molecule biomarkers faster than ever before.
Our discovery metabolomics and lipidomics screening leads us to the most biologically relevant signals, including molecules yet to be mapped.
Using our expansive commercial standards library, we can identify >700 known molecules in human plasma. We also map the thousands of unknown molecules we capture using 4D chemical characterization, which allows for accurate metabolite annotation.
Our next-generation mass spectrometry systems have an analytical cycle time of <1 minute, allowing us to process over 5,000 cellular, preclinical, and human samples per day.
That means you can have confidence in our capacity to generate results in less than 60 days on average, and maintain this turnaround time even for large-scale studies.
Given the dynamic complexity of small molecule biomarkers, it is critical to understand how they behave across populations of individuals representing different lifestyles, geographies, disease states, and timepoints.
Sapient’s Human Biology Database enables just that. Comprised of rLC-MS data and phenotypic information from 100,000+ biosamples with 10-30 years of clinical outcomes across patients, it allows us to:
You can leverage our discovery metabolomics and lipidomics services at any phase of the drug development pipeline, from early discovery to preclinical studies through clinical trials.
What are you looking to identify?
Submit a question or project request via the form, or click the button below to schedule a meeting with our scientists.
"*" indicates required fields